|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2000-5-25
|
|
pubmed:abstractText |
A randomized trial conducted by the Gynecologic Oncology Group (GOG, study #111) in the United States showed a better outcome for patients with advanced ovarian cancer on the paclitaxel-cisplatin regimen than for those on a standard cyclophosphamide-cisplatin regimen. Before considering the paclitaxel-cisplatin regimen as the new "standard," a group of European and Canadian investigators planned a confirmatory phase III trial.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0027-8874
|
|
pubmed:author |
pubmed-author:AndersenJ EJE,
pubmed-author:AtkinsonR JRJ,
pubmed-author:BaconMM,
pubmed-author:BaronBB,
pubmed-author:BertelsenKK,
pubmed-author:BirtAA,
pubmed-author:BlomRR,
pubmed-author:CassidyJJ,
pubmed-author:GrimshawRR,
pubmed-author:JamesKK,
pubmed-author:KaernJJ,
pubmed-author:KayeSS,
pubmed-author:LhoasFF,
pubmed-author:LindvallBB,
pubmed-author:MangioniCC,
pubmed-author:NardiMM,
pubmed-author:PaulJJ,
pubmed-author:PecorelliSS,
pubmed-author:PiccartM JMJ,
pubmed-author:RohJ RJR,
pubmed-author:SimonsenEE,
pubmed-author:StuartGG,
pubmed-author:SwenertonK DKD,
pubmed-author:TimmersPP,
pubmed-author:TropeCC,
pubmed-author:TumoloSS,
pubmed-author:VergoteII,
pubmed-author:ZehEE
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
3
|
|
pubmed:volume |
92
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
699-708
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10793106-Adult,
pubmed-meshheading:10793106-Aged,
pubmed-meshheading:10793106-Aged, 80 and over,
pubmed-meshheading:10793106-Alopecia,
pubmed-meshheading:10793106-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10793106-Cisplatin,
pubmed-meshheading:10793106-Combined Modality Therapy,
pubmed-meshheading:10793106-Cross-Over Studies,
pubmed-meshheading:10793106-Cyclophosphamide,
pubmed-meshheading:10793106-Disease Progression,
pubmed-meshheading:10793106-Female,
pubmed-meshheading:10793106-Follow-Up Studies,
pubmed-meshheading:10793106-Humans,
pubmed-meshheading:10793106-Middle Aged,
pubmed-meshheading:10793106-Nausea,
pubmed-meshheading:10793106-Neoplasm Staging,
pubmed-meshheading:10793106-Neutropenia,
pubmed-meshheading:10793106-Ovarian Neoplasms,
pubmed-meshheading:10793106-Paclitaxel,
pubmed-meshheading:10793106-Survival Analysis,
pubmed-meshheading:10793106-Thrombocytopenia,
pubmed-meshheading:10793106-Time Factors,
pubmed-meshheading:10793106-Treatment Outcome,
pubmed-meshheading:10793106-Vomiting
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
|
|
pubmed:affiliation |
European Organization for Research and Treatment of Cancer (EORTC)-Gynecological Cancer Cooperative Group, EORTC Data Center, Brussels, Belgium. mpiccart@ulb.ac.be
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III
|
